NURITAS LIMITED

Their core work

Nuritas is a Dublin-based biotech SME that uses artificial intelligence and bioinformatics to discover and validate bioactive peptides hidden within food proteins. Their core capability is predicting which peptide sequences, once released from food-grade raw materials, will produce specific health effects — then validating those predictions through clinical trials and securing regulatory recognition (EFSA health claims). They target high-value functional food and nutraceutical markets, translating computational biology into commercially viable food ingredients with clinically proven benefits.

What they specialise in

How they've shifted over time

Their initial H2020 engagement (2016) was firmly anchored in metabolic disease: diabetes prevention through food-derived peptides, with AI and bioinformatics as enabling tools and a clear commercial endpoint (EFSA claim, functional food market). By 2020 the application domain had broadened to ageing biology — specifically sarcopenia — suggesting the AI peptide-discovery platform is being applied to new health verticals beyond diabetes. The trajectory points toward a platform company strategy: the core technology (AI + peptides) stays constant while the health targets diversify.

Nuritas is expanding its AI-peptide discovery platform from metabolic disease into ageing and muscle health, suggesting future consortium interest in healthy ageing, sports nutrition, and precision nutrition verticals.

How they like to work

Nuritas consistently leads rather than joins: both H2020 projects were coordinated by Nuritas, and neither involved recorded consortium partners — a pattern typical of SME Instrument Phase 2 grants (single-company commercialisation projects) and MSCA Individual Fellowships (one researcher hosted by the company). This means Nuritas is not a habitual consortium builder; they operate as a self-contained innovation unit that brings in individual scientific talent rather than large research networks. A prospective partner should expect Nuritas to prefer lead or equal-partner roles, not subcontractor positions.

The available H2020 data records zero formal consortium partners and zero collaborating countries, which reflects the single-beneficiary structure of their grant types (SME Instrument Phase 2, MSCA-IF) rather than genuine isolation. Their real network — industry partners, clinical trial sites, and academic collaborators — is not visible in this dataset.

What sets them apart

Nuritas occupies a rare position at the intersection of computational biology and food science: they own a proprietary AI platform for peptide discovery and simultaneously hold the in-house capability to take a peptide from algorithm output through clinical trial to regulatory approval. Most food ingredient companies buy bioactives or license science; Nuritas generates its own IP from first principles. For a consortium building in precision nutrition, healthy ageing, or functional foods, they offer both the discovery engine and the commercialisation track record in a single SME partner.

Highlights from their portfolio

• PeptiEUForce
  One of the largest single-SME grants in the food-biotech space at €2.2M (SME Instrument Phase 2), spanning seven years and covering the full journey from AI-assisted peptide discovery to clinical trials and EFSA health claim — a complete proof-of-concept for Nuritas's platform.
• Pept-AGE
  An MSCA Individual Fellowship hosted by Nuritas that embedded academic muscle-biology research directly into a commercial AI pipeline, signalling the company's strategy of attracting top researchers to expand their peptide target portfolio into the ageing market.